Sign In

Use the Qualified Clinical Data Registry (QCDR) to complete Merit-Based Incentive Payment System reporting.

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

Oncology Practice Insider

ASCO’s Oncology Practice Insider provides the latest news, information, and educational tools to assist with the successful management of oncology practice and the delivery of high quality patient care. OPI offers updates on ASCO programs, services, and cancer-related health policy, Medicare news, and billing and coding best practices. To sign up for the biweekly Oncology Practice Insider newsletter, please complete this form.

On July 13, 2018, the Food and Drug Administration approved enzalutamide (XTANDI®, Astellas Pharma US, Inc.), for patients with castration-resistant prostate cancer (CRPC). This approval broadens the indicated patient population to include patients with both non-metastatic CRPC (NM-CRPC) and metastatic CRPC. Enzalutamide was previously approved for the treatment of patients with metastatic CRPC.
ASCO has launched “I Live to Conquer Cancer,” a new national outreach and awareness initiative that builds on ASCO’s continued advocacy activities and aims to underscore the critical importance of federally funded cancer research. This campaign includes a series of compelling videos, written stories, advertising, and social media that spotlights federally funded cancer researchers who have devoted their lives to clinical research, as well as the patients who inspire them to continue progress against cancer.
On July 10, 2018, the U.S. Food and Drug Administration granted accelerated approval to ipilimumab (YERVOY®, Bristol-Myers Squibb Company Inc.) for use in combination with nivolumab for the treatment of patients 12 years of age and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.
If you participated in the Merit-based Incentive Payment System (MIPS) in 2017, your MIPS final score and performance feedback is available for review on the Quality Payment Program website. If you believe an error has been made in your 2019 MIPS payment adjustment calculation, you can request a targeted review until September 30.
Register to attend the ASCO Oncology Practice Conference, September 27, 2018 at the JW Marriott Phoenix Desert Ridge in Phoenix, Arizona. This conference will address the challenges oncology practices face by discussing best practices and strategies to preserve the delivery of high-quality, cost-effective care.
ASCO President Monica M. Bertagnolli, MD, FACS, FASCO joined ASCO CEO Dr. Clifford Hudis for the latest ASCO in Action Podcast to discuss her presidential theme.   During the podcast, Dr. Bertagnolli says that we need to better understand the challenges that face a very diverse set of physicians and patients. “I think it's very clear to all of us that we cannot transform care, health care or oncology care, without more knowledge.”
Join us this summer for a Best of ASCO® Meeting in Washington, DC (August 3-4) or Chicago (August 10-11). Showcasing top research from ASCO 2018, the Best of ASCO Meetings will feature expert faculty leading in-depth discussion and analysis of the top scientific findings and practice-changing advances in cancer care.
The July 2018 HCPCS file includes a new Q code to describe an Injection of Retacrit for non-ESRD use.  As of July 1, 2018, Injection, epoetin alfa, biosimilar, (Retacrit) (for non-esrd use), 1000 units can be reported with Q5106.